.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Submacular hemorrhage management is critical for patients experiencing sudden and severe vision decline. This ophthalmic condition occurs when blood accumulates in the macular area between the neuroretina and the retinal pigment epithelium. Consequently, patients often notice a fixed, grayish-black scotoma in their central visual field. Therefore, clinicians must prioritize rapid diagnostic evaluation to prevent irreversible photoreceptor damage. Additionally, advanced multimodal imaging now provides essential support for determining the timing of adequate treatment.
Furthermore, various eye diseases like choroidal neovascularization in wet age-related macular degeneration frequently trigger these hemorrhages. However, systemic conditions such as hypertension also significantly influence the clinical course. Moreover, medications like antithrombotic drugs can exacerbate the severity of the subretinal bleed. Specifically, a holistic approach remains necessary to address these underlying factors while managing the acute ocular event.
The Manchester Protocol currently serves as a vital guideline for submacular hemorrhage management in modern clinical practice. In addition to conservative observation, this protocol outlines specific criteria for active intervention. For instance, if the hemorrhage exceeds the extent of two optic discs and occurs within two weeks, triple therapy becomes a viable option. This regimen involves the intravitreal injection of recombinant tissue plasminogen activator (rtPA), vascular endothelial growth factor (VEGF) inhibitors, and gas tamponade.
Thus, clinicians can effectively and safely displace the blood to allow for underlying retinal repair. Conversely, if triple therapy fails or if contraindications exist, surgical intervention like vitrectomy may become necessary. Ultimately, early and step-by-step intervention ensures the best possible functional outcomes and improves the patient's quality of life. Therefore, adhering to established protocols remains the cornerstone of successful therapy.
Patients typically report the sudden appearance of a fixed, grayish-black scotoma in their central field of vision, indicating macular involvement.
Triple therapy consists of intravitreal injections of rtPA to liquefy the clot, anti-VEGF agents to treat the underlying cause, and gas tamponade for pneumatic displacement.
Intervention should ideally occur within two weeks of symptom onset because prolonged blood exposure causes irreversible toxicity to the retinal photoreceptors.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Submacular hemorrhage is a vision-threatening condition often caused by wet AMD. Effective management relies on early intervention using the Manchester Protocol and triple therapy—rtPA, anti-VEGF, and gas—to displace blood and preserve central vision.
2 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
